Mucus is a selective barrier to particles and molecules, preventing penetration to the epithelial
surface of mucosal tissues. Significant advances in transmucosal drug delivery have …

There are a multitude of formulation factors to consider when developing a pMDI. Evaluation
of each of these variables has been performed over the years, but there has been an …

Biologic products are large molecules such as proteins, peptides, nucleic acids, etc., which
have already produced many new drugs for clinical use in the last decades. Due to the …

The performance of dry powder aerosols for the delivery of drugs to the lungs has been
studied extensively in the last decade. The focus for different research groups has been on …

Background Novel methods are necessary to reduce morbidity and mortality of patients
suffering from infections with Pseudomonas aeruginosa. Being the most common infectious …

This study involves a promising approach to achieve sustained pulmonary drug delivery. Dry
powder particulate carriers were engineered to allow simultaneous aerosol lung delivery, …

The pace of new research and level of innovation repeatedly introduced into the field of
drug delivery to the lung is surprising given its state of maturity since the introduction of the …

In recent years, several new genome editing technologies have been developed. Of these
the zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and …

Messenger RNA is a class of promising nucleic acid therapeutics to treat a variety of
diseases, including genetic diseases. The development of a stable and efficacious mRNA …

The objective of this study was to determine the effect of both carrier particle size and surface
roughness on the aerosol performance of dry powder formulations. Two morphologically …